Neurological Outcomes After Effect of COVID- 19

OVERVIEW

As the world still struggles to deal with the COVID-19 pandemic's effects, emerging evidence highlights significant neurological consequences that are affecting millions. The Neurological Outcomes After Effect of COVID-19 session will explore the wide range of neurological consequences associated with COVID-19, shedding light on how the virus has impacted the nervous system and what this means for long-term health.

Impact of COVID-19 on Neurological Health: This session will delve into how COVID-19 has been linked to a range of neurological issues, including cognitive impairment, headaches, anosmia (loss of smell), and more severe conditions such as stroke and encephalitis. Attendees will gain insights into the mechanisms through which SARS-CoV-2 affects the nervous system, including potential direct viral invasion and indirect effects through inflammatory responses.

Long-term Neurological Result of COVID-19: This segment will focus on long-term neurological sequelae observed in post-COVID patients. Attendees will examine studies and data on persistent symptoms such as brain fog, memory issues, and other cognitive deficits. The discussion will also cover the prevalence of these conditions, their impact on quality of life, and the challenges faced in managing these persistent symptoms.

Case Studies and Clinical Findings: Interactive case studies will be presented to illustrate real-world examples of neurological outcomes in COVID-19 patients. This section will encourage participants to engage with the data through case discussions and analysis, fostering a deeper understanding of the complexities involved in diagnosing and treating neurological complications.

Advances in Diagnosis and Treatment: Recent advancements in the diagnosis and treatment of COVID-19-related neurological issues will be highlighted. This session will include innovative diagnostic tools, emerging treatment protocols, and multidisciplinary approaches to managing neurological symptoms. Participants will have the opportunity to explore new research and discuss the implications for clinical practice.

Future Research Directions: Finally, This session will discuss the ongoing research and future directions needed to address the neurological impact of COVID-19. This will include identifying gaps in current knowledge, potential areas for further investigation, and the role of international collaboration in advancing our understanding and response to these neurological challenges.

TOPICS

Key Discussion Areas

Core scientific themes explored across all sessions in this track.

🔬

Interventional Cardiology Advances

Latest techniques in percutaneous coronary intervention, transcatheter structural interventions, and complex bifurcation stenting with outcome data from 2025–2026 trials.

💊

Heart Failure: New Drug Classes

Comprehensive review of SGLT2 inhibitors across HFrEF/HFpEF, mavacamten in HCM, and emerging agents in the pipeline with mechanisms and clinical trial evidence.

🤖

AI in Cardiac Imaging

Clinical validation data for AI tools in echocardiography, cardiac MRI, and CT angiography — including automated ejection fraction, plaque characterisation, and anomaly detection.

🧬

Cardiac Genetics & Cardiomyopathy

CRISPR applications in hereditary cardiomyopathy, genotype-guided risk stratification, and family screening protocols in hypertrophic and dilated cardiomyopathies.

⚡

Arrhythmia & Electrophysiology

Catheter ablation advances in persistent AF, ventricular tachycardia, and SCA prevention strategies including novel antiarrhythmic drug data and wearable monitoring.

🛡️

Preventive Cardiology

Polygenic risk scores in cardiovascular prevention, novel lipid-lowering strategies beyond statins, and population health approaches to primary cardiovascular prevention.

AUDIENCE

Who Should Attend?

This track is designed for clinicians, researchers, and allied health professionals with an interest in neurological outcomes after effect of covid- 19.

Cardiologists and cardiology trainees
Interventional cardiologists
Cardiac electrophysiologists
Heart failure specialists
Cardiothoracic surgeons
Clinical cardiac physiologists
Internal medicine physicians with cardiovascular interest
Cardiovascular nurses and allied health professionals
Cardiovascular researchers and clinical trialists

Attend Neurological Outcomes After Effect of COVID- 19

Join delegates from 120+ countries for three days of world-class clinical science at the Healthcore Bridge International Medical Conference 2026.

FAQs

Frequently Asked Questions

What is the scope of the Oncology & Haematology track?

The Oncology & Haematology track covers precision oncology, immunotherapy, ADC therapies, haematological malignancies, liquid biopsy and early detection, AI in oncology, and palliative care — across 22 sessions over three conference days. It is the largest scientific track at the 2026 conference.

Will there be separate sessions for haematology and solid tumours?

Yes. The track is structured with dedicated morning sessions for haematological malignancies and afternoon sessions focusing on solid tumour oncology. The final panel each day brings all specialties together for cross-disciplinary discussion.

Are there oncology workshops available?

Yes. Two hands-on workshops complement the oncology track: a molecular tumour board simulation workshop and an AI pathology interpretation masterclass. Both require separate registration due to a 30-delegate capacity limit.

Is this track accredited for oncology-specific CME?

All oncology sessions are accredited for CME under EACCME, AMA PRA Category 1, and the Royal College of Radiologists (for radiation oncologists). Specialty-specific CME credit allocation is detailed in the conference programme and the CME pre-event delegate guide.